首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷

市場調查報告書

商品編碼

1319148

全球數位病理市場 - 2023-2030 年

Global Digital Pathology Market - 2023-2030

出版日期: 2023年07月31日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

全球數位病理市場規模在2022 年達到9 億美元，預計到2030 年將實現利潤豐厚的成長，達到17 億美元。在預測期內（2023-2030 年），全球數位病理市場預計將呈現8.7% 的年複合成長率。遠程病理學和遠程會診的日益普及推動了數位病理學市場需求的成長趨勢。

數位病理學市場正經歷著顯著的成長和轉型。數位病理學涉及病理圖像的數位化和管理，使病理學家能夠以電子方式訪問和分析切片。這項技術具有眾多優勢，包括提高工作流程效率、加強協作、準確診斷，以及與人工智慧（AI）算法進行潛在整合以實現自動分析。

推動全球數位病理市場發展的因素包括：慢性病發病率不斷上升、人工智慧（AI）的整合、擴大採用數位病理技術提高實驗室效率、數位病理系統的技術進步、老年人口不斷增加以及數位病理技術在輔助診斷和藥物開發中的應用日益增多。

市場動態

擴大採用數位病理技術提高實驗室效率推動了數位病理市場的成長

傳統的病理操作需要使用玻璃載玻片，這些載玻片需要人工處理、存儲和運輸。這一過程既耗時又容易出錯。數位病理學無需使用實體玻片，病理學家可遠程訪問和分析圖像。這提高了工作流程效率，縮短了周轉時間，並提高了實驗室的整體生產率。

數位病理學還能促進病理學家之間的無縫協作。無論身處何地，都能輕鬆共享圖像、進行遠程會診和提供第二意見。病理學家可以即時協作，從而做出更準確的診斷，改善患者的治療效果。此外，數位病理學還能整合人工智慧（AI）和機器學習算法進行自動分析，進一步提高效率和準確性。

例如，2023 年6 月19 日，阿拉伯聯合大公國最大的醫院之一、阿布扎比醫療服務公司（SEHA）與梅奧診所的合資企業謝赫-沙赫布特醫療城（SSMC）啟動了其最先進的病理實驗室，該實驗室將支持SSMC 專家領導的病理團隊利用人工智慧工具和應用，最準確地診斷疾病和複雜病症。

輔助診斷和藥物開發應用的增加也推動了數位病理市場的成長

輔助診斷包括使用診斷測試來識別可能對特定治療方法產生反應的患者。數位病理學通過分析組織樣本和生物標記物來確定患者是否符合接受標靶治療的條件，在輔助診斷中發揮著至關重要的作用。數位病理平台可對基因突變或蛋白質表達等生物標記進行準確、標準化的評估，這對指導治療決策至關重要。

數位病理學還為藥物開發和研究做出了重大貢獻。它使製藥公司和研究人員能夠分析潛在候選藥物對組織樣本的影響。數位病理平台為臨床前和臨床試驗期間評估新藥的療效和安全性提供了標準化和可重複的方法。

通過自動圖像分析和利用人工智慧算法，數位病理學可幫助識別和量化藥物治療引起的細胞和分子變化。這加快了藥物開發過程，有助於就新療法的有效性和安全性做出明智決策。

例如，2023 年6 月22 日，高解析度定量數位病理學和人工智慧領域的領先企業PharmaNest Inc 宣布推出其數位病理學空間分辨定量組織面板，用於描述纖維化情況下組織損傷和炎症的嚴重程度，並允許對纖維化情況下的炎症進行新型人工智慧驅動的研究，適用於從發現模型到臨床開發的任何情況。

有限的標準化將阻礙市場成長。

數位病理學仍在不斷發展，在圖像格式、元數據和分析算法等各個方面都缺乏標準化。缺乏標準化協議和指南會給不同平台和機構之間的數據共享、比較和可重複性帶來挑戰。為克服這些挑戰，有必要努力實現標準化並在利益相關者之間開展合作。

COVID-19 影響分析

COVID-19 大流行對數位病理學市場產生了重大影響。大流行導致必須採取社會隔離措施，減少人際交往，從而使遠程診斷和遠程病理學變得至關重要。數位病理學使病理學家能夠遠程訪問和分析病理圖像，從而在最大程度降低病毒傳播風險的同時繼續提供診斷服務。大流行期間，對遠程會診和遠程病理解決方案的需求激增，推動了數位病理系統的採用。

俄烏戰爭影響分析

據估計，俄烏衝突對全球數位病理學市場的影響不大。由於衝突，數位病理學領域的國際合作和研究計劃可能面臨中斷。這可能會影響聯合項目的進展以及知識和資源的共享，從而可能減緩全球數位病理學市場的創新和進步。

F. Hoffmann-La Roche Ltd.
- 公司概況
- 產品組合和說明
- 財務概況
- 主要發展
Koninklijke Philips NV
Olympus Corporation
Leica Biosystems Nussloch GmbH (Danaher Corporation)
Hamamatsu Photonics, Inc.
Mikroscan Technologies Inc.
Inspirata, Inc. (Fujifilm)
Visiopharm A/S
Huron Technologies International Inc.
ContextVision AB

第15 章：附錄

簡介目錄

Product Code: HCIT1019

Market Overview

The global digital pathology market reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.7 billion by 2030. The global digital pathology market is expected to exhibit a CAGR of 8.7% during the forecast period (2023-2030). The increasing adoption of telepathology and remote consultation is driving up demand for digital pathology market trends.

The digital pathology market is experiencing significant growth and transformation. Digital pathology involves the digitization and management of pathology images, enabling pathologists to access and analyze slides electronically. This technology offers numerous advantages, including improved workflow efficiency, enhanced collaboration, accurate diagnosis, and potential integration with artificial intelligence (AI) algorithms for automated analysis.

The global digital pathology market is driven by the factors such as the increasing prevalence of chronic diseases, integration of artificial intelligence(AI), increasing adoption of digital pathology to enhance lab efficiency, technological advancements in digital pathology systems, the rising geriatric population, and increasing applications of digital pathology in companion diagnostics and drug development.

Market Dynamics

Increasing Adoption of Digital Pathology to Enhance Lab Efficiency Drives the Growth of the Digital Pathology Market

Traditional pathology practices involve the use of physical glass slides that require manual handling, storage, and transportation. This process can be time-consuming and prone to errors. Digital pathology eliminates the need for physical slides and enables pathologists to access and analyze images remotely. This enhances workflow efficiency, reduces turnaround times, and improves the overall productivity of the laboratory.

Digital pathology also facilitates seamless collaboration among pathologists. It allows for easy sharing of images, remote consultations, and second opinions, regardless of geographical location. Pathologists can collaborate in real time, leading to more accurate diagnoses and improved patient outcomes. Moreover, digital pathology enables the integration of artificial intelligence (AI) and machine learning algorithms for automated analysis, further enhancing efficiency and accuracy.

For instance, on June 19, 2023, Sheikh Shakhbout Medical City (SSMC), one of the UAE's largest hospitals and a joint-venture partnership between Abu Dhabi Health Services Company (SEHA) and Mayo Clinic, launched its state-of-the-art, Pathology Laboratory, which will support SSMC's expert-led pathology team in diagnosing disease and complex conditions with the utmost accuracy using AI-powered tools and applications.

Increasing Applications in Companion Diagnostics and Drug Development Also Drive the Growth of the Digital Pathology Market

Companion diagnostics involves using diagnostic tests to identify patients who are likely to respond to a specific therapeutic treatment. Digital pathology plays a crucial role in companion diagnostics by enabling the analysis of tissue samples and biomarkers to determine a patient's eligibility for targeted therapies. Digital pathology platforms provide an accurate and standardized assessment of biomarkers such as genetic mutations or protein expression, which are essential for guiding treatment decisions.

Digital pathology is also making significant contributions to drug development and research. It allows pharmaceutical companies and researchers to analyze the effects of potential drug candidates on tissue samples. Digital pathology platforms offer a standardized and reproducible method for assessing the efficacy and safety of new drugs during preclinical and clinical trials.

By automating image analysis and leveraging AI algorithms, digital pathology assists in identifying and quantifying cellular and molecular changes induced by drug treatments. This accelerates the drug development process and aids in making informed decisions regarding the efficacy and safety of new therapies.

For instance, on June 22, 2023, PharmaNest Inc, a leader in high-resolution quantitative Digital Pathology and Artificial Intelligence, announced the launch of its Digital Pathology spatially resolved, quantitative tissue panels to describe the severity of tissue injury and inflammation in the context of fibrotic conditions and allow novel AI-driven investigations of inflammation in the context of fibrosis for any condition, from discovery models to clinical development.

Limited Standardization will Hamper the Growth of the Market.

Digital pathology is still evolving, and there is a lack of standardization in various aspects, including image formats, metadata, and analytical algorithms. The absence of standardized protocols and guidelines can create challenges in data sharing, comparison, and reproducibility across different platforms and institutions. Efforts towards standardization and collaboration among stakeholders are necessary to overcome these challenges.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the digital pathology market. The pandemic necessitated social distancing measures and reduced in-person interactions, making remote diagnosis and telepathology essential. Digital pathology enabled pathologists to remotely access and analyze pathology images, allowing for continued diagnostic services while minimizing the risk of virus transmission. The demand for remote consultation and telepathology solutions surged during the pandemic, driving the adoption of digital pathology systems.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global digital pathology market. International collaborations and research initiatives in the field of digital pathology could face disruptions due to the conflict. This may affect the progress of joint projects and the sharing of knowledge and resources, potentially slowing down innovation and advancements in the global digital pathology market.

Segment Analysis

The global digital pathology market is segmented based on product, application, type, technology, end-user, and region.

Software from the Product Segment Accounts for 37.9% of the Digital Pathology Market Share

Digital pathology software offers advanced image analysis tools that assist pathologists in quantifying and analyzing tissue samples. These tools can automate certain tasks, such as cell counting, measuring biomarker expression, and identifying specific cellular structures. This enhances the efficiency and accuracy of diagnosis, reducing the reliance on manual analysis.

Software platforms in digital pathology increasingly integrate AI capabilities for automated analysis and pattern recognition. AI algorithms can assist in identifying anomalies, predicting disease outcomes, and providing decision support to pathologists. This integration enhances efficiency, accuracy, and consistency in diagnosis and allows for the discovery of new biomarkers and therapeutic targets.

Digital pathology software provides robust data management and storage capabilities. It enables the creation of centralized repositories for pathology images, patient data, and associated metadata. These repositories serve as valuable resources for research, quality assurance, and educational purposes. Software solutions ensure secure storage, retrieval, and sharing of digital pathology data while adhering to data protection regulations.

For instance, on June 8, 2023, Indica Labs announced the launch of a service offering deployment and ongoing support of its HALO digital pathology software in a fully managed cloud-hosted environment powered by Amazon Web Services (AWS). The service enables organizations to benefit from Indica Labs' software development and cloud deployment expertise while maintaining full ownership and control over their AWS account. Indica Labs' entire suite of HALO software, including the HALO Image Analysis platform, HALO AI deep learning classifier add-on, HALO Link browser-based image management system, and HALO AP anatomic pathology workflow platform, can now be deployed in professionally managed AWS cloud-hosted environments.

Geographical Analysis

North America Accounted for Approximately 39.8% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Presence of Major Players

North America boasts a well-developed and advanced healthcare infrastructure, including hospitals, diagnostic laboratories, and research institutions. The region has made significant investments in healthcare technologies, including digital pathology, to enhance patient care and diagnostic capabilities. The availability of state-of-the-art facilities and resources facilitates the adoption and implementation of digital pathology systems.

North America is home to several major players in the digital pathology market, including technology providers, software developers, and research organizations. These companies have made substantial investments in research and development, driving technological advancements and innovation in the field. The presence of established players with strong market positions contributes to the overall market growth and dominance of North America.

For instance, in September 2022, INFINITT North America, an award-winning developer of enterprise imaging solutions for healthcare, announced a collaboration with Hamamatsu Corporation to jointly promote Hamamatsu whole slide scanners (NanoZoomers) and INFINITT Digital Pathology Solution (IDPS) to its United States customers.

Competitive Landscape

The major global players in the digital pathology market include: F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., Olympus Corporation, Leica Biosystems Nussloch GmbH (Danaher Corporation), Hamamatsu Photonics, Inc., Mikroscan Technologies, Inc., Inspirata, Inc. (Fujifilm), Visiopharm A/S, Huron Technologies International Inc., and ContextVision AB.

Why Purchase the Report?

To visualize the global digital pathology market segmentation based on product, application, type, technology, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of digital pathology market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global digital pathology market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by Type
3.4. Snippet by Technology
3.5. Snippet by End-User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Adoption of Digital Pathology to Enhance Lab Efficiency
  - 4.1.1.2. Increasing Applications in Companion Diagnostics and Drug Developments
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Digital Pathology Systems
- 4.1.3. Opportunity
  - 4.1.3.1. Technological Advancements in Digital Pathology Systems
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Software *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Scanners
7.4. Storage Systems
7.5. Communication Systems
7.6. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Drug Discovery *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Teleconsultation
8.4. Diagnosis
8.5. Training & Education
8.6. Others

9. By Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.1.2. Market Attractiveness Index, By Type
9.2. Human Pathology *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Veterinary Pathology

10. By Technology

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.1.2. Market Attractiveness Index, By Technology
10.2. Whole Slide Imaging *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Telepathology
- 10.3.1. Static Telepathology
- 10.3.2. Dynamic Telepathology

11. By End-User

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.2. Market Attractiveness Index, By End-User
11.2. Hospital Laboratories *
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Pharmaceutical And Biotechnology Companies
11.4. Contract Research Organizations
11.5. Research & Academic Institutes
11.6. Others

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.8.1. U.S.
  - 12.2.8.2. Canada
  - 12.2.8.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.8.1. Germany
  - 12.3.8.2. U.K.
  - 12.3.8.3. France
  - 12.3.8.4. Spain
  - 12.3.8.5. Italy
  - 12.3.8.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. Brazil
  - 12.4.8.2. Argentina
  - 12.4.8.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.8.1. China
  - 12.5.8.2. India
  - 12.5.8.3. Japan
  - 12.5.8.4. Australia
  - 12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. Company Profiles

14.1. F. Hoffmann-La Roche Ltd. *
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. Koninklijke Philips N.V.
14.3. Olympus Corporation
14.4. Leica Biosystems Nussloch GmbH (Danaher Corporation)
14.5. Hamamatsu Photonics, Inc.
14.6. Mikroscan Technologies Inc.
14.7. Inspirata, Inc. (Fujifilm)
14.8. Visiopharm A/S
14.9. Huron Technologies International Inc.
14.10. ContextVision AB

LIST NOT EXHAUSTIVE